Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in Pseudomonas aeruginosa Bacteremia: 12-Year Experience in a Tertiary Hospital in Korea
CONCLUSION: The identification of risk factors for antimicrobial resistance and analysis of antimicrobial susceptibility might be important for concordant empirical antimicrobial therapy in patients with P. aeruginosa bacteremia.PMID:34751008 | DOI:10.3346/jkms.2021.36.e273
This study will use a multicentre, open-label non-inferiority trial design comparing cefiderocol and standard of care antibiotics. Eligible participants will be adult inpatients who are diagnosed with a bloodstream infection with a Gram-negative organism on the basis of a positive blood culture result where the acquisition meets the definition for healthcare-associated or hospital-acquired. It will compare cefiderocol with the current standard of care (SOC) antibiotic regimen according to the patient ’s treating clinician. Eligible participants will be randomised 1:1 to cefiderocol or SOC and receive 5–14&thins...
ConclusionsThe combination of fosfomycin and doxycycline should be evaluated further with additional LRVREF isolates. In vivo studies should also be performed prior to usage in clinical situations.
Authors: Bader MS, Loeb M, Leto D, Brooks AA Abstract Urinary tract infections (UTIs) caused by antibiotic- resistant Gram-negative bacteria are a growing concern due to limited treatment options. Knowledge of the common uropathogens in addition to local susceptibility patterns is essential in determining appropriate empiric antibiotic therapy of UTIs. The recommended first-line empiric antibiotic therapy for acute uncomplicated bacterial cystitis in otherwise healthy adult nonpregnant females is a 5-day course of nitrofurantion, a 3-g single dose of fosfomycin tromethamine, or a 5-day course of pevmecillinam. High...
Conclusion: New carbapenem/βLI combinations may be viable alternatives to antimicrobial combination therapy as they displayed high efficacy in vitro and in vivo. Meropenem/Avibactam and Meropenem/Relebactam should be tested on larger sample sizes with different carbapenemases before progressing further in its preclinical development. Introduction Carbapenem resistant Gram-negative bacteria have been gradually increasing in prevalence in recent years. In the United States, the latest CDC Antibiotic Resistance Threat Report indicates that Carbapenem-Resistant Enterobacteriaceae (CREs) are responsible for 9,000 a...
ConclusionsThe emergence of coexistence of carbapenemase genes and mcr-1 in Enterobacteriaceae highlights a serious threat to antimicrobial therapy.
ConclusionsThe emergency of coexistence of carbapenemase genes and mcr-1 in Enterobacteriaceae highlights the serious threat to antimicrobial therapy.
ConclusionThis case underlines the emergence of multidrug resistantMyroides spp. which are ubiquitous in the environment and it demands that clinicians should be more mindful about the role played by atypical pathogens, which may harbour or express multidrug resistant characteristics, in immunocompromised patients or where there is a failure of empiric antimicrobial therapy.
Conclusions: After the care bundle approach is adopted in our PICU, DA-HAIs are expected to decrease further.